Tian Xiaoyan, Fu Kunling, Huang Xuemin, Zou Haiyan, Shi Nianmei, Li Jiayang, Bao Yuxiang, He Sisi, Lv Junyuan
The First Clinical Institute, Zunyi Medical University, Zunyi, Guizhou, China.
Office of Drug Clinical Trial Institution, The Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Front Pharmacol. 2024 Aug 13;15:1430561. doi: 10.3389/fphar.2024.1430561. eCollection 2024.
Ferroptosis represents a distinct form of cell death that is not associated with necrosis, autophagy, apoptosis, or pyroptosis. It is characterised by intracellular iron-dependent lipid peroxidation. The current literature indicates that a number of botanical drugs and isolated metabolites can modulate ferroptosis, thereby exerting inhibitory effects on lung cancer cells or animal models. The aim of this review is to elucidate the mechanisms through which botanical drugs and isolated metabolites regulate ferroptosis in the context of lung cancer, thereby providing potential insights into lung cancer treatment. It is crucial to highlight that these preclinical findings should not be interpreted as evidence that these treatments can be immediately translated into clinical applications. In the future, we will continue to study the pharmacology, pharmacokinetics and toxicology of these drugs, as well as evaluating their efficacy and safety in clinical trials, with the aim of providing new approaches to the development of new agents for the treatment of lung cancer.
铁死亡是一种独特的细胞死亡形式，与坏死、自噬、凋亡或焦亡无关。其特征是细胞内铁依赖性脂质过氧化。目前的文献表明，许多植物药和分离出的代谢产物可以调节铁死亡，从而对肺癌细胞或动物模型产生抑制作用。本综述的目的是阐明植物药和分离出的代谢产物在肺癌背景下调节铁死亡的机制，从而为肺癌治疗提供潜在的见解。必须强调的是，这些临床前研究结果不应被解释为这些治疗方法可立即转化为临床应用的证据。未来，我们将继续研究这些药物的药理学、药代动力学和毒理学，并评估它们在临床试验中的疗效和安全性，以期为开发治疗肺癌的新型药物提供新方法。
